G1/S restriction point coordinates phasic gene expression and cell differentiation.

Nat Commun

The Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research, Center for Reproductive Sciences, University of California San Francisco, San Francisco, CA, USA.

Published: June 2022

Pluripotent embryonic stem cells have a unique cell cycle structure with a suppressed G1/S restriction point and little differential expression across the cell cycle phases. Here, we evaluate the link between G1/S restriction point activation, phasic gene expression, and cellular differentiation. Expression analysis reveals a gain in phasic gene expression across lineages between embryonic days E7.5 and E9.5. Genetic manipulation of the G1/S restriction point regulators miR-302 and P27 respectively accelerates or delays the onset of phasic gene expression in mouse embryos. Loss of miR-302-mediated p21 or p27 suppression expedites embryonic stem cell differentiation, while a constitutive Cyclin E mutant blocks it. Together, these findings uncover a causal relationship between emergence of the G1/S restriction point with a gain in phasic gene expression and cellular differentiation.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9237072PMC
http://dx.doi.org/10.1038/s41467-022-31101-0DOI Listing

Publication Analysis

Top Keywords

g1/s restriction
20
restriction point
20
phasic gene
20
gene expression
20
expression cell
8
cell differentiation
8
embryonic stem
8
cell cycle
8
expression cellular
8
cellular differentiation
8

Similar Publications

Increased endothelial cell proliferation is a hallmark of arteriovenous malformations (AVMs) in hereditary hemorrhagic telangiectasia (HHT). Here, we report a cyclin-dependent kinase 6 (CDK6)-driven mechanism of cell cycle deregulation involved in endothelial cell proliferation and HHT pathology. Specifically, endothelial cells from the livers of HHT mice bypassed the G1/S checkpoint and progressed through the cell cycle at an accelerated pace.

View Article and Find Full Text PDF

Impaired control of the G1/S checkpoint allows initiation of DNA replication under non-permissive conditions. Unscheduled S-phase entry is associated with DNA replication stress, demanding for other checkpoints or cellular pathways to maintain proliferation. Here, we uncovered a requirement for ADARp150 to sustain proliferation of G1/S-checkpoint-defective cells under growth-restricting conditions.

View Article and Find Full Text PDF

Anti-EGFR Antibody-Drug Conjugate Carrying an Inhibitor Targeting CDK Restricts Triple-Negative Breast Cancer Growth.

Clin Cancer Res

August 2024

Breast Cancer Now Research Unit, School of Cancer and Pharmaceutical Sciences, King's College London, Guy's Cancer Centre, London, United Kingdom.

Article Synopsis
  • Anti-EGFR antibodies have limited effectiveness in breast cancer due to compensatory pathways and resistance in triple-negative breast cancer (TNBC) from CDK2/cyclin E expression; however, a cetuximab-based antibody drug conjugate (ADC) incorporating a CDK inhibitor may improve targeted treatment.
  • In experimental designs, researchers evaluated the expressions of cell cycle regulators alongside EGFR and developed an ADC, combining cetuximab with CDK inhibitor SNS-032, to specifically deliver treatment to EGFR-expressing cancer cells.
  • Results showed that the ADC effectively inhibited tumor growth, induced cytotoxic effects on high EGFR-expressing cells, and demonstrated potential for improved targeting in aggressive breast cancer types, highlighting the importance
View Article and Find Full Text PDF

Inhibition of amino acid transporter LAT1 in cancer cells suppresses G0/G1-S transition by downregulating cyclin D1 via p38 MAPK activation.

J Pharmacol Sci

March 2024

Department of Bio-system Pharmacology, Graduate School of Medicine, Osaka University, 2-2 Yamadaoka, Suita, Osaka, 565-0871, Japan; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives (OTRI), Osaka University, Suita, Osaka, 565-0871, Japan. Electronic address:

L-type amino acid transporter 1 (LAT1, SLC7A5) is upregulated in various cancers and associated with disease progression. Nanvuranlat (Nanv; JPH203, KYT-0353), a selective LAT1 inhibitor, suppresses the uptake of large neutral amino acids required for rapid growth and proliferation of cancer cells. Previous studies have suggested that the inhibition of LAT1 by Nanv induces the cell cycle arrest at G0/G1 phase, although the underlying mechanisms remain unclear.

View Article and Find Full Text PDF

Unlabelled: Regulation of RNA polymerase II (Pol II) transcription is closely associated with cell proliferation. However, it remains unclear how the Pol II transcription program is altered in cancer to favour cell growth. Here, we find that gene expression of , a known negative elongation factor, is up-regulated in colorectal tumours.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!